Back
Podium Abstract
Eposter Presentation
 
Accept format: PDF. The file size should not be more than 5MB
 
Accept format: PNG/JPG/WEBP. The file size should not be more than 2MB
 
Submitted
Abstract
Heterogeneity of [68Ga] Ga‑PSMA‑11 PET/CT in the assessment of therapy response in metastatic renal cell carcinoma treated with immune checkpoint inhibitors plus tyrosine kinase inhibitors
Podium Abstract
Clinical Research
Oncology: Kidney (non-UTUC)
Author's Information
4
No more than 10 authors can be listed (as per the Good Publication Practice (GPP) Guidelines).
Please ensure the authors are listed in the right order.
China
Shao-Hao Chen Chen shaohao.chen@fjmu.edu.cn The First Affiliated Hospital of Fujian Medical University Fuzhou China *
Xiao-Hui Wu 1257135259@qq.com The First Affiliated Hospital of Fujian Medical University Fuzhou China -
Xue-Yi Xue xuexueyi@fjmu.edu.cn The First Affiliated Hospital of Fujian Medical University Fuzhou China -
Ning Xu drxun@fjmu.edu.cn The First Affiliated Hospital of Fujian Medical University Fuzhou China -
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract Content
This study aimed to assess the predictive significance of 68Ga-labeled prostate-specific membrane antigen-11 positron emission tomography/computerized tomography ([68Ga] Ga-PSMA-11 PET/CT) for evaluating treatment response in patients with metastatic renal cell carcinoma (mRCC) undergoing treatment with tyrosine kinase inhibitors (TKIs) in combination with immune checkpoint inhibitors (ICIs).
This retrospective study included 108 patients with mRCC who underwent [68Ga] Ga-PSMA-11 PET/CT and were treated with TKIs plus ICIs between January 2019 and March 2023. Evaluation of therapeutic response to treatment with TKIs plus ICIs was based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines. Logistic regression analysis was used to determine independent predictors of response to TKIs plus ICIs. Kaplan-Meier analyses and receiver operating characteristics curve (ROC) analyses were performed to evaluate the performance of the independent predictors. RNA sequencing, bioinformatics analyses, immunohistochemistry (IHC), and immunofluorescence (IF) staining were performed to reveal the tumor microenvironment.
Among the 108 patients with mRCC, twelve (11.11%) experienced a complete response (CR), 24 (22.22%) experienced a partial response (PR), 45 (41.67%) experienced stable disease (SD), and 27 (25.00%) experienced progressive disease (PD). On [68Ga] Ga-PSMA-11 PET/CT, the area under the curve of a cumulative standardized uptake value (SUV)-volume histogram (AUC-CSH) (P <0.001) and SUVmax (P=0.001) were independent predictors of response to treatment with TKIs plus ICIs in patients with mRCC. The AUC-CSH for predicting treatment response was 0.812 (95% CI:0.678–0.908), and the SUVmax was 0.757 (95% CI:0.625–0.872). Lower PSMA heterogeneity and higher [68Ga] Ga-PSMA-11 SUVmax both correlated with increased progression-free survival (PFS). Further analyses of the tumor environment revealed that regions with PSMA heterogeneity were enriched with M2 macrophages and cancer-associated fibroblast (CAFs) cells, whereas low PSMA heterogeneity clusters were enriched in CD8+ T cells, and M1 macrophages. Patients with low PSMA heterogeneity had significantly higher levels of immune checkpoint expression than patients with high PSMA heterogeneity, and their Tumor Immune Dysfunction and Exclusion scores were significantly lower than those of patients with high PSMA heterogeneity.
In patients with mRCC, PSMA heterogeneity and [68Ga] Ga-PSMA-11 SUVmax were associated with response to therapy with TKIs plus ICIs.
metastatic renal cell carcinoma; tyrosine kinase inhibitors; immune checkpoint inhibitors; PSMA PET/CT; tumor environment
https://storage.unitedwebnetwork.com/files/1237/c6364a325b8f03e223509bbc1f1f7088.jpg
Figure 1. Diagrammatic representation of the study. [68Ga] Ga-PSMA-11 PET/CT: 68Ga-labeled prostate-specific membrane antigen-11 positron emission tomography/computerized tomography; CR: complete response; PR: partial response; SD: stable disease; PD
https://storage.unitedwebnetwork.com/files/1237/68f59077f5d5f8718a20915c5cc42e65.jpg
Figure 2. Schematic diagram of the AUC-CSH of [68Ga] Ga-PSMA-11 PET/CT in patients with mRCC. (A) PET imaging, CT imaging, and the corresponding CSH histogram in a patient with low heterogeneity (AUC-CSH, 0.648). (B) PET imaging, CT imaging, and the
https://storage.unitedwebnetwork.com/files/1237/dcfc49a8f644093d3497ac35e65d1f46.jpg
Figure 3. Receiver operating characteristics curve analysis and Kaplan-Meier analysis of PFS. (A-B) For PSMA heterogeneity; (C-D) for PSMA SUVmax. PSMA heterogeneity was computed as AUC-CSH values, and higher AUC-CSH values indicate lower PSMA hetero
https://storage.unitedwebnetwork.com/files/1237/696a9f06992225e6d3f627d393c2ae6e.jpg
Figure 4. Correlation between PSMA heterogeneity of tumor lesions and response to treatment with TKIs plus ICIs. PSMA AUC-CSH values (A) and PSMA SUVmax (B) in different types of tumor metastasis lesions. (C-F) The relationship between the PSMA heter
https://storage.unitedwebnetwork.com/files/1237/c900e562f2395fb2c1d8c166f6166f31.jpg
Figure 5. Functional enrichment and tumor microenvironment analyses between high and low PSMA heterogeneity groups. (A, B) GSEA analyses indicates the top enriched pathways. (C, D) CIBERSORT analysis reveals the infiltration levels of different immun
2417
 
Presentation Details
Free Paper Podium(10): Oncology RCC (A)
Aug. 15 (Fri.)
16:30 - 16:36
11